JP2013516190A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013516190A5 JP2013516190A5 JP2012548108A JP2012548108A JP2013516190A5 JP 2013516190 A5 JP2013516190 A5 JP 2013516190A5 JP 2012548108 A JP2012548108 A JP 2012548108A JP 2012548108 A JP2012548108 A JP 2012548108A JP 2013516190 A5 JP2013516190 A5 JP 2013516190A5
- Authority
- JP
- Japan
- Prior art keywords
- c3pi
- c3ps
- c3oh
- molecule
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002773 nucleotide Substances 0.000 claims 16
- 125000003729 nucleotide group Chemical group 0.000 claims 16
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 208000035657 Abasia Diseases 0.000 claims 5
- 150000004713 phosphodiesters Chemical class 0.000 claims 5
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine group Chemical group [C@@H]1([C@H](O)[C@H](O)[C@@H](CO)O1)N1C=NC=2C(N)=NC=NC12 OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims 4
- 230000000692 anti-sense effect Effects 0.000 claims 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 3
- 108091081021 Sense strand Proteins 0.000 claims 3
- 230000000295 complement effect Effects 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 3
- 108020004414 DNA Proteins 0.000 claims 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 229910052816 inorganic phosphate Inorganic materials 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- MXHRCPNRJAMMIM-SHYZEUOFSA-N 2'-deoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-SHYZEUOFSA-N 0.000 claims 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 claims 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims 1
- 102000053602 DNA Human genes 0.000 claims 1
- 108091034117 Oligonucleotide Proteins 0.000 claims 1
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 claims 1
- 229960005305 adenosine Drugs 0.000 claims 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 claims 1
- 239000005547 deoxyribonucleotide Substances 0.000 claims 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 claims 1
- MXHRCPNRJAMMIM-UHFFFAOYSA-N desoxyuridine Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-UHFFFAOYSA-N 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 125000002652 ribonucleotide group Chemical group 0.000 claims 1
- DWRXFEITVBNRMK-JXOAFFINSA-N ribothymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 DWRXFEITVBNRMK-JXOAFFINSA-N 0.000 claims 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 claims 1
- 229940045145 uridine Drugs 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29287810P | 2010-01-07 | 2010-01-07 | |
| US61/292,878 | 2010-01-07 | ||
| USPCT/US2010/049047 | 2010-09-16 | ||
| PCT/US2010/049047 WO2011084193A1 (en) | 2010-01-07 | 2010-09-16 | Oligonucleotide compounds comprising non-nucleotide overhangs |
| PCT/US2011/020298 WO2011085056A1 (en) | 2010-01-07 | 2011-01-06 | Oligonucleotide compounds comprising non-nucleotide overhangs |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013516190A JP2013516190A (ja) | 2013-05-13 |
| JP2013516190A5 true JP2013516190A5 (enExample) | 2014-01-30 |
| JP5824463B2 JP5824463B2 (ja) | 2015-11-25 |
Family
ID=44305677
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012548108A Expired - Fee Related JP5824463B2 (ja) | 2010-01-07 | 2011-01-06 | 非ヌクレオチドオーバーハングを含むオリゴヌクレオチド化合物 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US8859751B2 (enExample) |
| EP (1) | EP2521783B1 (enExample) |
| JP (1) | JP5824463B2 (enExample) |
| CN (1) | CN102770541B (enExample) |
| ES (1) | ES2640091T3 (enExample) |
| WO (2) | WO2011084193A1 (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5685267B2 (ja) | 2009-12-09 | 2015-03-18 | 日東電工株式会社 | Ｈｓｐ４７発現の調節 |
| RU2012153703A (ru) * | 2010-06-24 | 2014-07-27 | Кварк Фармасьютикалс, Инк. | Соединения двухцепочечных рнк к rhoa и их применение |
| EP2631291B1 (en) | 2010-10-22 | 2019-05-15 | OliX Pharmaceuticals, Inc. | Nucleic acid molecules inducing rna interference, and uses thereof |
| US20130324591A1 (en) | 2010-12-06 | 2013-12-05 | Quark Pharmaceuticals, Inc. | Double stranded oligonucleotide compounds comprising positional modifications |
| WO2012118911A1 (en) | 2011-03-03 | 2012-09-07 | Quark Pharmaceuticals, Inc. | Oligonucleotide modulators of the toll-like receptor pathway |
| US9796979B2 (en) | 2011-03-03 | 2017-10-24 | Quark Pharmaceuticals Inc. | Oligonucleotide modulators of the toll-like receptor pathway |
| EP2773758B1 (en) | 2011-11-03 | 2017-06-07 | Quark Pharmaceuticals, Inc. | Compositions for use in neuroprotection |
| WO2013070821A1 (en) | 2011-11-08 | 2013-05-16 | Quark Pharmaceuticals, Inc. | Methods and compositions for treating diseases, disorders or injury of the nervous system |
| CN104080480A (zh) | 2012-01-01 | 2014-10-01 | 奇比艾企业有限公司 | 用于选择性递送治疗剂和诊断剂的endo180靶向微粒 |
| US9382542B2 (en) * | 2012-01-04 | 2016-07-05 | Quark Pharmaceuticals, Inc. | Double-stranded RNA compounds to CASP2 and uses thereof |
| US9707235B1 (en) * | 2012-01-13 | 2017-07-18 | University Of Kentucky Research Foundation | Protection of cells from degeneration and treatment of geographic atrophy |
| DK2853597T3 (en) | 2012-05-22 | 2019-04-08 | Olix Pharmaceuticals Inc | RNA INTERFERENCE-INducing NUCLEIC ACID MOLECULES WITH CELL PENETENING EQUIPMENT AND USE THEREOF |
| AU2013315524B2 (en) | 2012-09-12 | 2019-01-31 | Quark Pharmaceuticals, Inc. | Double-stranded oligonucleotide molecules to p53 and methods of use thereof |
| DK2895607T3 (da) | 2012-09-12 | 2021-05-25 | Quark Pharmaceuticals Inc | Dobbeltstrengede oligonukleotidmolekyler til ddit4 og fremgangsmåder til anvendelse deraf |
| US10006024B2 (en) * | 2012-11-29 | 2018-06-26 | Gifu University | RNA interference agent, method for producing same, and use therefor |
| EP3027223A1 (en) | 2013-07-31 | 2016-06-08 | QBI Enterprises Ltd. | Methods of use of sphingolipid polyalkylamine oligonucleotide compounds |
| US9889200B2 (en) | 2013-07-31 | 2018-02-13 | Qbi Enterprises Ltd. | Sphingolipid-polyalkylamine-oligonucleotide compounds |
| KR101696704B1 (ko) | 2013-12-17 | 2017-01-16 | 주식회사 인코드젠 | 오프-타겟을 막기 위해 변형된 rna 간섭 유도 핵산 및 그 용도 |
| LT3149172T (lt) | 2014-05-29 | 2018-09-10 | Quark Pharmaceuticals, Inc. | Būdai ir kompozicijos, skirti organų išeminės reperfuzijos pažeidimo prevencijai |
| WO2016149020A1 (en) * | 2015-03-17 | 2016-09-22 | Arrowhead Research Corporation | Rna interference agents |
| SI3350333T1 (sl) | 2015-09-17 | 2022-04-29 | ModernaTX,Inc. | Polinukleotidi, ki zajemajo stabilizacijsko repno regijo |
| EP3377630A4 (en) | 2015-11-16 | 2020-01-01 | Olix Pharmaceuticals, Inc. | Treatment of age-related macular degeneration using rna complexes that target myd88 or tlr3 |
| JP6944942B2 (ja) | 2016-02-02 | 2021-10-06 | オリックス ファーマシューティカルズ，インコーポレーテッド | ＩＬ４Ｒα、ＴＲＰＡ１、またはＦ２ＲＬ１を標的とするＲＮＡ複合体を用いたアトピー性皮膚炎および喘息の治療 |
| EP3411481A4 (en) | 2016-02-02 | 2020-02-26 | Olix Pharmaceuticals, Inc. | TREATMENT OF DISEASES ASSOCIATED WITH ANGIOGENESIS USING ANGPT2 AND PDGFB TARGETED RNA COMPLEXES |
| WO2017178883A2 (en) | 2016-04-11 | 2017-10-19 | Olix Pharmaceuticals, Inc. | Treatment of idiopathic pulmonary fibrosis using rna complexes that target connective tissue growth factor |
| KR101916652B1 (ko) | 2016-06-29 | 2018-11-08 | 올릭스 주식회사 | 작은 간섭 rna의 rna 간섭효과 증진용 화합물 및 이의 용도 |
| AU2017368050A1 (en) | 2016-11-29 | 2019-06-20 | Puretech Lyt, Inc. | Exosomes for delivery of therapeutic agents |
| EP3580339A4 (en) | 2017-02-10 | 2020-12-23 | Research & Business Foundation Sungkyunkwan University | LONG DOUBLE STRAND RNA FOR RNA INTERFERENCE |
| WO2020191177A1 (en) * | 2019-03-21 | 2020-09-24 | Sudhir Agrawal | Antisense oligonucleotides for allele specificity |
| AU2020450890B2 (en) * | 2020-05-26 | 2025-04-10 | Olix Pharmaceuticals, Inc. | RNAi agent targeting MyD88 and use thereof |
| JP2024504503A (ja) * | 2021-01-30 | 2024-01-31 | イー セラピューティクス パブリック リミテッド カンパニー | 脱塩基ヌクレオチドを含有する核酸 |
| WO2022162155A1 (en) * | 2021-01-30 | 2022-08-04 | E-Therapeutics Plc | Nucleic acids containing abasic nucleotides |
| WO2023059948A1 (en) * | 2021-10-08 | 2023-04-13 | E-Therapeutics Plc | Nucleic acids containing abasic nucleosides |
| EP4562148A1 (en) * | 2022-07-27 | 2025-06-04 | E-Therapeutics plc | Nucleic acid compounds |
| EP4562147A1 (en) * | 2022-07-27 | 2025-06-04 | E-Therapeutics plc | Nucleic acid compounds |
| KR20250043473A (ko) * | 2022-07-27 | 2025-03-28 | 이-테라퓨틱스 피엘씨 | 핵산 화합물 |
| WO2024165571A2 (en) * | 2023-02-06 | 2024-08-15 | E-Therapeutics Plc | Inhibitors of expression and/or function |
| WO2025125576A2 (en) * | 2023-12-15 | 2025-06-19 | E-Therapeutics Plc | Inhibitors of expression and/or function |
| EP4686757A1 (en) * | 2024-07-31 | 2026-02-04 | e-therapeutics PLC | Inhibitors of expression and/or function |
Family Cites Families (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| US4959217A (en) | 1986-05-22 | 1990-09-25 | Syntex (U.S.A.) Inc. | Delayed/sustained release of macromolecules |
| US4925678A (en) | 1987-04-01 | 1990-05-15 | Ranney David F | Endothelial envelopment drug carriers |
| US5080646A (en) | 1988-10-03 | 1992-01-14 | Alza Corporation | Membrane for electrotransport transdermal drug delivery |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5270030A (en) | 1988-12-29 | 1993-12-14 | Bio-Technology General Corp. | Fibrin binding domain polypeptide and method of producing |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| US5167616A (en) | 1989-12-14 | 1992-12-01 | Alza Corporation | Iontophoretic delivery method |
| US5378825A (en) | 1990-07-27 | 1995-01-03 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogs |
| US5225182A (en) | 1991-10-31 | 1993-07-06 | Sharma Yash P | Vectored drug delivery system using a cephaloplastin linking agent and a methed of using the system |
| KR940703846A (ko) | 1991-12-24 | 1994-12-12 | 비. 린네 파샬 | 갭(gap)이 형성된 2′ 변성된 올리고뉴클레오티드(gapped 2′ modifed oligonucleotides) |
| WO1993023569A1 (en) | 1992-05-11 | 1993-11-25 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for inhibiting viral replication |
| US6235886B1 (en) | 1993-09-03 | 2001-05-22 | Isis Pharmaceuticals, Inc. | Methods of synthesis and use |
| US5593972A (en) | 1993-01-26 | 1997-01-14 | The Wistar Institute | Genetic immunization |
| WO1995006731A2 (en) | 1993-09-02 | 1995-03-09 | Ribozyme Pharmaceuticals, Inc. | Non-nucleotide containing enzymatic nucleic acid |
| US5998203A (en) | 1996-04-16 | 1999-12-07 | Ribozyme Pharmaceuticals, Inc. | Enzymatic nucleic acids containing 5'-and/or 3'-cap structures |
| US20050042647A1 (en) | 1996-06-06 | 2005-02-24 | Baker Brenda F. | Phosphorous-linked oligomeric compounds and their use in gene modulation |
| US20080119427A1 (en) | 1996-06-06 | 2008-05-22 | Isis Pharmaceuticals, Inc. | Double Strand Compositions Comprising Differentially Modified Strands for Use in Gene Modulation |
| US5898031A (en) | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
| US20050032067A1 (en) | 2002-11-05 | 2005-02-10 | Prakash Thazha P. | Non-phosphorous-linked oligomeric compounds and their use in gene modulation |
| JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
| US6251666B1 (en) | 1997-03-31 | 2001-06-26 | Ribozyme Pharmaceuticals, Inc. | Nucleic acid catalysts comprising L-nucleotide analogs |
| CA2303299C (en) | 1997-09-12 | 2016-02-23 | Exiqon A/S | Oligonucleotide analogues |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| WO2000044914A1 (en) | 1999-01-28 | 2000-08-03 | Medical College Of Georgia Research Institute, Inc. | Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna |
| DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| PT1152009E (pt) | 1999-02-12 | 2005-03-31 | Sankyo Co | Novos analogos de nucleosidos e oligonucleotidos |
| WO2000049035A1 (en) | 1999-02-19 | 2000-08-24 | The General Hospital Corporation | Gene silencing |
| JP2000290185A (ja) * | 1999-04-08 | 2000-10-17 | Sankyo Co Ltd | Ｔｇｇｇ配列を持つ修飾オリゴデオキシリボヌクレオチドを含有する抗エイズ剤 |
| CA2370628A1 (en) | 1999-04-21 | 2000-10-26 | American Home Products Corporation | Methods and compositions for inhibiting the function of polynucleotide sequences |
| EP1235842A4 (en) | 1999-10-15 | 2003-04-23 | Univ Massachusetts | Rna interference pathway genes as tools for targeted genetic interference |
| GB9925459D0 (en) | 1999-10-27 | 1999-12-29 | Plant Bioscience Ltd | Gene silencing |
| DE60041452D1 (de) | 1999-11-02 | 2009-03-12 | Novartis Vaccines & Diagnostic | CpG REZEPTOR (CpG-R) UND DARAUF BEZOGENE METHODEN |
| GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
| US7829693B2 (en) | 1999-11-24 | 2010-11-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a target gene |
| US20050020525A1 (en) | 2002-02-20 | 2005-01-27 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| WO2003070918A2 (en) | 2002-02-20 | 2003-08-28 | Ribozyme Pharmaceuticals, Incorporated | Rna interference by modified short interfering nucleic acid |
| US8202979B2 (en) | 2002-02-20 | 2012-06-19 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid |
| WO2001068836A2 (en) | 2000-03-16 | 2001-09-20 | Genetica, Inc. | Methods and compositions for rna interference |
| ATE450621T2 (de) | 2000-03-30 | 2009-12-15 | Whitehead Biomedical Inst | Mediatoren von rns-interferenz, die rns- sequenzspezifisch sind |
| US6693187B1 (en) | 2000-10-17 | 2004-02-17 | Lievre Cornu Llc | Phosphinoamidite carboxlates and analogs thereof in the synthesis of oligonucleotides having reduced internucleotide charge |
| KR100872437B1 (ko) | 2000-12-01 | 2008-12-05 | 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. | Ｒｎａ 간섭을 매개하는 작은 ｒｎａ 분자 |
| US20040019001A1 (en) | 2002-02-20 | 2004-01-29 | Mcswiggen James A. | RNA interference mediated inhibition of protein typrosine phosphatase-1B (PTP-1B) gene expression using short interfering RNA |
| US20070032441A1 (en) | 2001-05-18 | 2007-02-08 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (sina) |
| ES2401326T3 (es) | 2001-11-21 | 2013-04-18 | Astellas Pharma Inc. | Procedimiento para inhibir la expresión génica |
| WO2003064621A2 (en) | 2002-02-01 | 2003-08-07 | Ambion, Inc. | HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES |
| US20050096289A1 (en) * | 2002-02-07 | 2005-05-05 | Hans Prydz | Methods and compositions for modulating tissue factor |
| ATE449846T1 (de) * | 2002-02-07 | 2009-12-15 | Sirnasense As | Post-transcriptional silencing der gewebefaktor expression durch kurze interferierende rnas |
| AU2003207708A1 (en) | 2002-02-20 | 2003-09-09 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of map kinase genes |
| ES2280826T5 (es) | 2002-08-05 | 2017-08-03 | Silence Therapeutics Gmbh | Nuevas formas adicionales de moléculas de ARN de interferencia |
| US9150605B2 (en) | 2002-11-05 | 2015-10-06 | Isis Pharmaceuticals, Inc. | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
| JP2006507841A (ja) | 2002-11-14 | 2006-03-09 | ダーマコン， インコーポレイテッド | 機能的ｓｉＲＮＡおよび超機能的ｓｉＲＮＡ |
| US20050233342A1 (en) | 2003-03-07 | 2005-10-20 | Muthiah Manoharan | Methods of preventing off-target gene silencing |
| US8653252B2 (en) | 2003-03-21 | 2014-02-18 | Santaris Pharma A/S | Short interfering RNA (siRNA) analogues |
| AU2004252442B2 (en) | 2003-06-02 | 2010-04-08 | University Of Massachusetts | Methods and compositions for enhancing the efficacy and specificity of FNAi |
| ES2712695T3 (es) | 2003-06-02 | 2019-05-14 | Univ Massachusetts | Métodos y composiciones para controlar la eficacia de la silenciación del ARN |
| US20060241072A1 (en) | 2003-06-20 | 2006-10-26 | Isis Pharmaceuticals, Inc. | Oligomeric compounds for use in gene modulation |
| KR101147147B1 (ko) | 2004-04-01 | 2012-05-25 | 머크 샤프 앤드 돔 코포레이션 | Ｒｎａ 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드 |
| JP5192234B2 (ja) | 2004-08-10 | 2013-05-08 | アルナイラム ファーマシューティカルズ， インコーポレイテッド | 化学修飾オリゴヌクレオチド |
| JP4468989B2 (ja) | 2004-08-16 | 2010-05-26 | クアーク・ファーマスーティカルス、インコーポレイテッド | Ｒｔｐ８０１阻害剤の治療への使用 |
| US20110313024A1 (en) | 2004-08-20 | 2011-12-22 | Leonid Beigelman | RNA INTERFERENCE MEDIATED INHIBITION OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9 (PCSK9) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| EP1812569A2 (en) | 2004-11-08 | 2007-08-01 | K.U. Leuven Research and Development | Modified nucleosides for rna interference |
| US20090176725A1 (en) * | 2005-08-17 | 2009-07-09 | Sirna Therapeutics Inc. | Chemically modified short interfering nucleic acid molecules that mediate rna interference |
| WO2007031877A2 (en) * | 2005-09-16 | 2007-03-22 | Coley Pharmaceutical Gmbh | Modulation of immunostimulatory properties of short interfering ribonucleic acid (sirna) by nucleotide modification |
| WO2007087451A2 (en) | 2006-01-25 | 2007-08-02 | University Of Massachusetts | Compositions and methods for enhancing discriminatory rna interference |
| GB0608838D0 (en) | 2006-05-04 | 2006-06-14 | Novartis Ag | Organic compounds |
| CA2662704A1 (en) | 2006-07-07 | 2008-01-10 | University Of Massachusetts | Rna silencing compositions and methods for the treatment of huntington's disease |
| JP2010507387A (ja) | 2006-10-25 | 2010-03-11 | クアーク・ファーマスーティカルス、インコーポレイテッド | 新規のｓｉＲＮＡおよびその使用方法 |
| WO2008104978A2 (en) | 2007-02-28 | 2008-09-04 | Quark Pharmaceuticals, Inc. | Novel sirna structures |
| US7812002B2 (en) | 2007-03-21 | 2010-10-12 | Quark Pharmaceuticals, Inc. | Oligoribonucleotide inhibitors of NRF2 and methods of use thereof for treatment of cancer |
| CN103898110A (zh) | 2007-10-03 | 2014-07-02 | 夸克制药公司 | 新siRNA结构 |
| US8188060B2 (en) * | 2008-02-11 | 2012-05-29 | Dharmacon, Inc. | Duplex oligonucleotides with enhanced functionality in gene regulation |
| DK2504435T3 (da) | 2009-11-26 | 2019-12-09 | Quark Pharmaceuticals Inc | Sirna-forbindelser omfattende terminale substitutioner |
| JP5685267B2 (ja) | 2009-12-09 | 2015-03-18 | 日東電工株式会社 | Ｈｓｐ４７発現の調節 |
| US20130324591A1 (en) | 2010-12-06 | 2013-12-05 | Quark Pharmaceuticals, Inc. | Double stranded oligonucleotide compounds comprising positional modifications |
-
2010
- 2010-09-16 WO PCT/US2010/049047 patent/WO2011084193A1/en not_active Ceased
-
2011
- 2011-01-06 EP EP11701706.1A patent/EP2521783B1/en not_active Not-in-force
- 2011-01-06 CN CN201180011234.0A patent/CN102770541B/zh not_active Expired - Fee Related
- 2011-01-06 ES ES11701706.1T patent/ES2640091T3/es active Active
- 2011-01-06 JP JP2012548108A patent/JP5824463B2/ja not_active Expired - Fee Related
- 2011-01-06 WO PCT/US2011/020298 patent/WO2011085056A1/en not_active Ceased
- 2011-01-06 US US13/521,033 patent/US8859751B2/en active Active
-
2014
- 2014-09-15 US US14/485,828 patent/US9249414B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014509511A5 (enExample) | ||
| NZ599237A (en) | Sirna compounds comprising terminal substitutions | |
| JP2016513976A5 (enExample) | ||
| JP7348922B2 (ja) | Ｂ型肝炎感染の治療用のＰＡＰＤ５及びＰＡＰＤ７ ｍＲＮＡを低減させるための核酸分子 | |
| JP2021531022A5 (enExample) | ||
| JP2014511686A5 (enExample) | ||
| JP2021533804A5 (enExample) | ||
| JP7515400B2 (ja) | Ｂ型肝炎ウイルス感染を治療するためのｆｕｂｐ１阻害剤の使用 | |
| JP2009524696A5 (enExample) | ||
| JP2012050438A5 (enExample) | ||
| JP2019534009A5 (enExample) | ||
| JP2019503394A5 (enExample) | ||
| JP2016116520A5 (enExample) | ||
| JP2014527401A5 (enExample) | ||
| JP2009514877A5 (enExample) | ||
| JP2016520312A5 (enExample) | ||
| JP2009543783A5 (enExample) | ||
| JP2007505627A5 (enExample) | ||
| JP2005517436A5 (enExample) | ||
| JP2013510561A5 (enExample) | ||
| JP2016502858A5 (enExample) | ||
| CN105008533A (zh) | 嵌合单链反义多核苷酸和双链反义试剂 | |
| JP2010512747A5 (enExample) | ||
| JP2013537404A5 (enExample) | ||
| JP2012505657A5 (enExample) |